Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 151 No. 1718 (2021)

Insurance coverage policies for reconstructive lymphatic microsurgery procedures in Switzerland

  • Semra Uyulmaz
  • Agnes Fejes
  • Lisanne Grünherz
  • Pietro Giovanoli
  • Nicole Lindenblatt
Cite this as:
Swiss Med Wkly. 2021;151:w20456



Lymphoedema is a progressive and potentially disabling disease. A growing number of studies show promising clinical results after microsurgical reconstruction. However, this treatment is currently not supported by level 1 evidence and insurance coverage is variable.


Electronic records of 55 patients with limb lymphoedema, who were eligible for lymphovenous bypass surgery and/or lymphatic tissue transfer in our department from 2017 to 2020, were reviewed. Correspondence between our department and health insurers was analysed. A web-based search and individual telephone interviews were conducted to identify health insurer policies.


We included 42 patients undergoing 46 operations and evaluated the correspondence between our department and nine different health insurers. Overall, reimbursement of costs was approved in 67% (n = 31) of all surgeries and was refused in 33% (n = 15). The mean number of applications for reconsideration sent to insurers was 1.3 ± 0.7. The time between confirmation of the indication and the final decision ranged from 6 to 300 days (mean 50 days). Reimbursement of cost coverage ranged from 0% to 100% depending on the individual insurance company. No insurance company had policies publicly available online and all stated that they determine coverage only when provided with specific patient details on a case-by-case basis.


Insurance companies in Switzerland do not have a uniform policy regarding cost coverage for lymphatic surgery procedures. Moreover, the decision process appeared to be rather uniform within the respective insurance company and independent of the individual case. Standardised evaluation criteria including patient reported outcome measures should be developed to underscore the beneficial effects of lymphatic surgery and facilitate insurance coverage.


  1. Grada AA, Phillips TJ. Lymphedema: Pathophysiology and clinical manifestations. J Am Acad Dermatol. 2017;77(6):1009–20. doi:.
  2. Vignes S, Fau-Prudhomot P, Simon L, Sanchez-Bréchot ML, Arrault M, Locher F. Impact of breast cancer-related lymphedema on working women. Support Care Cancer. 2020;28(1):79–85. doi:.
  3. Chachaj A, Małyszczak K, Pyszel K, Lukas J, Tarkowski R, Pudełko M, et al. Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment. Psychooncology. 2010;19(3):299–305. doi:.
  4. Oliveri JM, Day JM, Alfano CM, Herndon JE, 2nd, Katz ML, Bittoni MA, et al. Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804. J Cancer Surviv. 2008;2(4):233–42. doi:.
  5. Voogd AC, Ververs JM, Vingerhoets AJ, Roumen RM, Coebergh JW, Crommelin MA. Lymphoedema and reduced shoulder function as indicators of quality of life after axillary lymph node dissection for invasive breast cancer. Br J Surg. 2003;90(1):76–81. doi:.
  6. Uzkeser H, Karatay S, Erdemci B, Koc M, Senel K. Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial. Breast Cancer. 2015;22(3):300–7. doi:.
  7. Vignes S, Porcher R, Arrault M, Dupuy A. Long-term management of breast cancer-related lymphedema after intensive decongestive physiotherapy. Breast Cancer Res Treat. 2007;101(3):285–90. doi:.
  8. Koshima I, Nanba Y, Tsutsui T, Takahashi Y, Itoh S. Long-term follow-up after lymphaticovenular anastomosis for lymphedema in the leg. J Reconstr Microsurg. 2003;19(4):209–16. doi:.
  9. Chung JH, Baek SO, Park HJ, Lee BI, Park SH, Yoon ES. Efficacy and patient satisfaction regarding lymphovenous bypass with sleeve-in anastomosis for extremity lymphedema. Arch Plast Surg. 2019;46(1):46–56. doi:.
  10. Chang DW, Suami H, Skoracki R. A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg. 2013;132(5):1305–14. doi:.
  11. Rosian K, Stanak M. Efficacy and safety assessment of lymphovenous anastomosis in patients with primary and secondary lymphoedema: A systematic review of prospective evidence. Microsurgery. 2019;39(8):763–72. doi:.
  12. Forte AJ, Huayllani MT, Boczar D, Ciudad P, Manrique O. Lipoaspiration and lymph node transfer for treatment of breast cancer-related lymphedema: A systematic review. Cureus. 2019;11(11):e6096. doi:.
  13. Ciudad P, Agko M, Perez Coca JJ, Manrique OJ, Chang WL, Nicoli F, et al. Comparison of long-term clinical outcomes among different vascularized lymph node transfers: 6-year experience of a single center’s approach to the treatment of lymphedema. J Surg Oncol. 2017;116(6):671–82. doi:.
  14. Ozturk CN, Ozturk C, Glasgow M, Platek M, Ashary Z, Kuhn J, et al. Free vascularized lymph node transfer for treatment of lymphedema: A systematic evidence based review. J Plast Reconstr Aesthet Surg. 2016;69(9):1234–47. doi:.
  15. Rosian K, Stanak M. Lymphovenous anastomoses in patients with primary and secondary lymphoedema. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; 2018. Decision Support Document No. 110.
  16. Tzou CJ, Steinbacher J, Czedik-Eysenberg M, Brandstaetter S, Meng S, Schuetz M, et al. Institutionalization of reconstructive lymphedema surgery in Austria-Single center experience. J Surg Oncol. 2020;121(1):91–9. doi:.
  17. Nielubowicz J, Olszewski W. Experimental lymphovenous anastomosis. Br J Surg. 1968;55(6):449–51. doi:.
  18. S2k Guideline - Diagnostics and Therapy of Lymphedema, AWMF Reg.No. 058-001, May 2017. Available at: -001l_S2k_Diagnostik_und_Therapie_der_Lymphoedeme_2017-05.pdf, p. 49 [accessed 2017 August 4]
  19. Hirche C, Engel H, Seidenstuecker K, Taeger C, Machens HG, Frick A, et al. Rekonstruktive Mikrochirurgie des sekundären Lymphödems: Konsensus der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der peripheren Nerven und Gefäße (DAM) zur Indikation, Diagnostik und Therapie mittels Lymphovenöser Anastomosen (LVA) und vaskularisierter Lymphknotentransplantation (VLKT) [Lympho-reconstructive microsurgery for secondary lymphedema: Consensus of the German-Speaking Society for Microsurgery of Peripheral Nerves and Vessels (DAM) on indication, diagnostic and therapy by lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT)]. Handchir Mikrochir Plast Chir. 2019;51(6):424–33. Article in German. doi:htps://
  20. [Internet]. Switzerland: Bundesamt für Gesundheit BAG; c2020 [cited 2020 Mar 27]. Available from:
  21. [Internet]. Switzerland: Entscheidsuche Kantonales Gericht des Kantons St. Gallen; c2020 [cited 2020 Mar 27]. Available from:
  22. [Internet]. Switzerland: Entscheidsuche Kantonales Gericht des Kantons Waadt; c2020 [cited 2020 Mar 27]. Available from:
  23. Head LK, Momtazi M. Economics of lymphovenous bypass. Plast Reconstr Surg. 2019;144(5):751e–9e. doi:.
  24. Coriddi M, Dayan J, Sobti N, Nash D, Goldberg J, Klassen A, et al. Systematic review of patient reported outcomes following surgical treatment of lymphedema. Cancers (Basel). 2020;12(3):565. doi:.
  25. Chang EI, Ibrahim A, Liu J, Robe C, Suami H, Hanasono MM, et al. Optimizing quality of life for patients with breast cancer-related lymphedema: A prospective study combining DIEP flap breast reconstruction and lymphedema surgery. Plast Reconstr Surg. 2020;145(4):676e–85e. doi:.

Most read articles by the same author(s)